What is Metastatic Prostate Cancer?
Metastatic prostate cancer means that cancer has spread beyond the prostate gland to other parts of the body, most commonly the bones and lymph nodes. It is different from localized prostate cancer, where the disease is limited to the prostate and may often be treated with surgery, radiotherapy, or active surveillance depending on risk. In metastatic disease, treatment focuses on controlling cancer growth, reducing symptoms, preserving quality of life, and improving survival.
Prostate cancer may remain silent in the early stages. Some men notice urinary symptoms such as frequent urination, difficulty starting urine, weak urine flow, blood in urine, or waking up repeatedly at night to pass urine. When the cancer has spread to bones, patients may develop persistent back pain, hip pain, pelvic pain, fatigue, unexplained weight loss, or weakness. These symptoms should never be ignored, especially in men above 50 years of age or those with a family history of prostate cancer.
How Prostate Cancer Is Diagnosed
The PSA blood test plays an important role in prostate cancer evaluation. PSA is not a cancer test by itself, because levels can also rise due to benign prostate enlargement, infection, inflammation, or recent urinary procedures. However, a persistently raised PSA, abnormal prostate examination, or suspicious imaging finding requires proper assessment by a urologist. Diagnosis is usually confirmed with prostate imaging and biopsy, while scans such as PSMA PET-CT, CT scan, MRI, or bone scan may be used to understand whether the cancer has spread.
Treatment Options for Metastatic Prostate Cancer
Treatment for metastatic prostate cancer has changed significantly in the last decade. Earlier, androgen deprivation therapy, also known as ADT or hormonal therapy, was the main treatment. ADT lowers testosterone activity because prostate cancer cells often depend on androgen signals for growth. Today, evidence supports intensifying treatment in many patients by combining ADT with newer hormonal agents, chemotherapy, or selected targeted therapies depending on disease burden, patient fitness, symptoms, and cancer biology.
Advanced hormonal medicines such as androgen receptor pathway inhibitors may help improve disease control when added to ADT in suitable patients. Chemotherapy may be recommended in selected cases, especially when the cancer burden is high or the disease is more aggressive. In some patients, genetic or molecular testing may help identify whether targeted therapy is appropriate. If cancer has spread to bones, additional treatment may be needed to reduce pain, protect bone health, and prevent skeletal complications.
Every patient with metastatic prostate cancer is different. Treatment decisions should not be based only on PSA value. A complete evaluation includes symptoms, imaging results, biopsy grade, spread pattern, general health, kidney and liver function, age, other medical conditions, and patient preference. This is why consultation with an experienced uro-oncology specialist is important. Patients can also read general staging and treatment information from the National Cancer Institute.
Consult a Uro-Oncology Specialist in Lucknow
Dr. Manmeet Singh, Director, Department of Urology at Medanta Lucknow, manages complex urological cancers including prostate cancer, kidney cancer, bladder cancer, and advanced uro-oncology cases. Patients from Lucknow, Gomti Nagar, Hazratganj, Indira Nagar, Kanpur, Ayodhya, Rae Bareli, Sitapur, and nearby regions consult for evidence-based prostate cancer treatment in Lucknow and treatment planning.
If you or a loved one has been diagnosed with advanced prostate cancer, do not delay specialist consultation. With timely diagnosis, proper staging, and modern treatment planning, many patients can achieve better symptom control, improved quality of life, and longer disease control.
Book Consultation: +91-9278164041